Testing a drug combination with focused radiation for melanoma that spread to the brain
Original title: Bevacizumab and ICIs + hSRT in Symptomatic Melanoma Brain Metastases
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is an early test in people, checking safety first.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study tests three cancer drugs together with focused radiation for melanoma brain tumors.
Who this trial is for. This trial is for people with melanoma that has spread to the brain and is causing symptoms. It tests the drug bevacizumab: A drug that acts on the blood vessels a tumor builds. In brain tumors it is used mainly for two things. One is to control symptoms from swelling. The other is to cut down how much steroid someone needs. See the glossary, given with ipilimumab and nivolumab, plus a focused form of radiation called hSRT. Everyone in the trial gets the same treatment plan.
Where it stands. This trial has not reported results. It is looking at how safe this combination is and how well it works. Those answers are not in yet.
What this means, and what it doesn't
What it could mean: Someone with melanoma brain tumors that cause symptoms may want to know about this study. If that sounds like you, you can ask your care team about it. They can help you see if it fits your situation.
What it doesn't mean: This does not mean the treatment works. A trial is a test, not a proven treatment. Being in a trial is not a promise that it will help you. It is not a cure.
Source: ClinicalTrials.gov, October 13, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.